Deborah Sterling’s Post

Check out Director Jorge Goldstein, Ph.D.'s article, "Solutions to the Problem of Therapeutic Antibody Genus Claims," featured in the latest edition of American Intellectual Property Law Association (AIPLA)'s Quarterly Journal. https://gag.gl/Qx9VQi Jorge, after analyzing decades of enablement and written description case law, proposes creative claim-drafting solutions to one of the most controversial problems in modern biotechnology patents: How to obtain enforceable claims to a genus of antibodies or their uses. Biopharma patent practitioners will find valuable insights on strategies to prosecute, assert, and defend such genus claims. #Biotech #TherapeuticAntibodies

Check out Director Jorge Goldstein, Ph.D.'s article, "Solutions to the Problem of Therapeutic Antibody Genus Claims," featured in the latest edition of American Intellectual Property Law Association (AIPLA)'s Quarterly Journal. https://gag.gl/Qx9VQi Jorge, after analyzing decades of enablement and written description case law, proposes creative claim-drafting solutions to one of the most controversial problems in modern biotechnology patents: How to obtain enforceable claims to a genus of antibodies or their uses. Biopharma patent practitioners will find valuable insights on strategies to prosecute, assert, and defend such genus claims. #Biotech #TherapeuticAntibodies

Check out Director Jorge Goldstein, Ph.D.'s article, "Solutions to the Problem of Therapeutic Antibody Genus Claims," featured in the latest edition of American Intellectual Property Law Association (AIPLA)'s Quarterly Journal. https://gag.gl/Qx9VQi Jorge, after analyzing decades of enablement and written description case law, proposes creative claim-drafting solutions to one of the most controversial problems in modern biotechnology patents: How to obtain enforceable claims to a genus of antibodies or their uses. Biopharma patent practitioners will find valuable insights on strategies to prosecute, assert, and defend such genus claims. #Biotech #TherapeuticAntibodies

Check out Director Jorge Goldstein, Ph.D.'s article, "Solutions to the Problem of Therapeutic Antibody Genus Claims," featured in the latest edition of American Intellectual Property Law Association (AIPLA)'s Quarterly Journal. https://gag.gl/Qx9VQi Jorge, after analyzing decades of enablement and written description case law, proposes creative claim-drafting solutions to one of the most controversial problems in modern biotechnology patents: How to obtain enforceable claims to a genus of antibodies or their uses. Biopharma patent practitioners will find valuable insights on strategies to prosecute, assert, and defend such genus claims. #Biotech #TherapeuticAntibodies

Check out Director Jorge Goldstein, Ph.D.'s article, "Solutions to the Problem of Therapeutic Antibody Genus Claims," featured in the latest edition of American Intellectual Property Law Association (AIPLA)'s Quarterly Journal. https://gag.gl/Qx9VQi Jorge, after analyzing decades of enablement and written description case law, proposes creative claim-drafting solutions to one of the most controversial problems in modern biotechnology patents: How to obtain enforceable claims to a genus of antibodies or their uses. Biopharma patent practitioners will find valuable insights on strategies to prosecute, assert, and defend such genus claims. #Biotech #TherapeuticAntibodies

Check out Director Jorge Goldstein, Ph.D.'s article, "Solutions to the Problem of Therapeutic Antibody Genus Claims," featured in the latest edition of American Intellectual Property Law Association (AIPLA)'s Quarterly Journal. https://gag.gl/Qx9VQi Jorge, after analyzing decades of enablement and written description case law, proposes creative claim-drafting solutions to one of the most controversial problems in modern biotechnology patents: How to obtain enforceable claims to a genus of antibodies or their uses. Biopharma patent practitioners will find valuable insights on strategies to prosecute, assert, and defend such genus claims. #Biotech #TherapeuticAntibodies

Check out Director Jorge Goldstein, Ph.D.'s article, "Solutions to the Problem of Therapeutic Antibody Genus Claims," featured in the latest edition of American Intellectual Property Law Association (AIPLA)'s Quarterly Journal. https://gag.gl/Qx9VQi Jorge, after analyzing decades of enablement and written description case law, proposes creative claim-drafting solutions to one of the most controversial problems in modern biotechnology patents: How to obtain enforceable claims to a genus of antibodies or their uses. Biopharma patent practitioners will find valuable insights on strategies to prosecute, assert, and defend such genus claims. #Biotech #TherapeuticAntibodies

Check out Director Jorge Goldstein, Ph.D.'s article, "Solutions to the Problem of Therapeutic Antibody Genus Claims," featured in the latest edition of American Intellectual Property Law Association (AIPLA)'s Quarterly Journal. https://gag.gl/Qx9VQi Jorge, after analyzing decades of enablement and written description case law, proposes creative claim-drafting solutions to one of the most controversial problems in modern biotechnology patents: How to obtain enforceable claims to a genus of antibodies or their uses. Biopharma patent practitioners will find valuable insights on strategies to prosecute, assert, and defend such genus claims. #Biotech #TherapeuticAntibodies

Check out Director Jorge Goldstein, Ph.D.'s article, "Solutions to the Problem of Therapeutic Antibody Genus Claims," featured in the latest edition of American Intellectual Property Law Association (AIPLA)'s Quarterly Journal. https://gag.gl/Qx9VQi Jorge, after analyzing decades of enablement and written description case law, proposes creative claim-drafting solutions to one of the most controversial problems in modern biotechnology patents: How to obtain enforceable claims to a genus of antibodies or their uses. Biopharma patent practitioners will find valuable insights on strategies to prosecute, assert, and defend such genus claims. #Biotech #TherapeuticAntibodies

Check out Director Jorge Goldstein, Ph.D.'s article, "Solutions to the Problem of Therapeutic Antibody Genus Claims," featured in the latest edition of American Intellectual Property Law Association (AIPLA)'s Quarterly Journal. https://gag.gl/Qx9VQi Jorge, after analyzing decades of enablement and written description case law, proposes creative claim-drafting solutions to one of the most controversial problems in modern biotechnology patents: How to obtain enforceable claims to a genus of antibodies or their uses. Biopharma patent practitioners will find valuable insights on strategies to prosecute, assert, and defend such genus claims. #Biotech #TherapeuticAntibodies